<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773524</url>
  </required_header>
  <id_info>
    <org_study_id>AG0315OG</org_study_id>
    <nct_id>NCT02773524</nct_id>
  </id_info>
  <brief_title>A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer</brief_title>
  <acronym>INTEGRATEIIa</acronym>
  <official_title>A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Australasian Gastro-Intestinal Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academic and Community Cancer Research United</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Australasian Gastro-Intestinal Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib :&#xD;
      placebo)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:&#xD;
&#xD;
      The purpose of this Phase III study is to determine if regorafenib improves overall survival&#xD;
      in patients with Advanced Gastro-Oesophageal Carcinoma.&#xD;
&#xD;
      Who is it for:&#xD;
&#xD;
      You may be eligible to join this study if you are aged 18 years or above and have been&#xD;
      diagnosed with advanced (metastatic or locally recurrent) Gastro-Oesophageal Carcinoma which&#xD;
      has not responded to a minimum of 2 lines of prior anti-cancer therapy.&#xD;
&#xD;
      Trial Details:&#xD;
&#xD;
      Participants will be randomly (by chance) allocated to one of two groups: regorafenib or&#xD;
      placebo in 2:1 ratio respectively and will not be aware of their group allocation.&#xD;
      Regorafenib or matching placebo will be self-administered by participants orally once daily&#xD;
      on days 1-21 of each 28 days cycle. Treatment will continue until disease progression or&#xD;
      prohibitive toxicity. Participants will be followed up every 2-4 weeks in order to evaluate&#xD;
      their progress on the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From time of patient randomisation until date last known alive (up to 12 months following end of treatment).</time_frame>
    <description>The interval from the date of randomisation to date of death from any cause, or the date last known alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From time of patient randomisation until first evidence of disease progression or death (up to 12 months following randomisation).</time_frame>
    <description>The interval from the date of randomisation to the date of first evidence of disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumour Response Rate</measure>
    <time_frame>From time of patient randomisation until evidence of complete or partial response (up to 12 months following randomisation).</time_frame>
    <description>The OTRR will be calculated by summing the number of participants in a given arm that are assessed as having a complete or partial response (as per RECIST criteria), and dividing this by the total number of participants in the corresponding arm of the analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of health states experienced by participants</measure>
    <time_frame>From time of commencement of treatment until first evidence of disease progression (up to 12 months following commencement of treatment).</time_frame>
    <description>Questionnaire used to assess quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Adverse Events</measure>
    <time_frame>From time dose of study treatment until 30 days after last dose of study treatment</time_frame>
    <description>A descriptive analysis of the adverse events (AE) data will be prepared for participants in the safety population. The number and percentage of participants who experience AEs will be tabulated according to CTCAE term/category, grade, and seriousness.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Identification of tumour markers to that predict treatment outcomes for AGOC</measure>
    <time_frame>Up to 24 months following close of recruitment.</time_frame>
    <description>Biomarker assessment, CTC DNA assessment to predict whether treatment for AGOC is efficacious</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of regorafenib Maximum Plasma Concentration [Cmax] between Asia and Rest of World cohorts.</measure>
    <time_frame>Up to 24 months following close of recruitment.</time_frame>
    <description>Evaluation of regorafenib Maximum Plasma Concentration [Cmax] in patients from either Asia or ROW to assess whether genetic factors aide/hinder metabolic rate of consumption of regorafenib</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Gastro-Oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.</description>
    <arm_group_label>Regorafenib</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Adults (18 years or over) with metastatic or locally recurrent gastro-oesophageal&#xD;
             cancer which:&#xD;
&#xD;
               1. has arisen in any primary gastro-oesophageal site (oesophago-gastric junction&#xD;
                  (GOJ) or stomach); and&#xD;
&#xD;
               2. is of adenocarcinoma or undifferentiated carcinoma histology , and&#xD;
&#xD;
               3. is evaluable according to Response Evaluation Criteria in Solid Tumours (RECIST&#xD;
                  Version 1.1) by computed tomography (CT) scan performed within 21 days prior to&#xD;
                  randomisation. A lesion in a previously irradiated area is eligible to be&#xD;
                  considered as measurable disease as long as there is objective evidence of&#xD;
                  progression of the lesion prior to study enrolment; and&#xD;
&#xD;
               4. has failed or been intolerant to a minimum of 2 lines of prior anti-cancer&#xD;
                  therapy for recurrent/metastatic disease which must have included at least one&#xD;
                  platinum agent and one fluoropyrimidine analogue.&#xD;
&#xD;
                  Note: Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy will be&#xD;
                  considered as first line treatment where people have relapsed or progressed&#xD;
                  within 6 months of completing treatment; Radiosensitising chemotherapy given&#xD;
                  solely for this purpose concurrent with palliative radiation will not be&#xD;
                  considered as a line of treatment. Ramucirumab monotherapy, or immunotherapy with&#xD;
                  a checkpoint inhibitor, will be considered a line of treatment.&#xD;
&#xD;
               5. HER2-positive participants must have received trastuzumab.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          3. Ability to swallow oral medication.&#xD;
&#xD;
          4. Adequate bone marrow function (Platelets ≥100x109/L; Absolute Neutrophil Count (ANC)&#xD;
             ≥1.5x109/L and Haemoglobin ≥ 9.0g/dL).&#xD;
&#xD;
          5. Adequate renal function (Creatinine clearance &gt;50 ml/min) based on either the&#xD;
             Cockcroft-Gault formula (Appendix 2), 24-hour urine or Glomerular Filtration Rate&#xD;
             (GFR) scan; and serum creatinine ≤1.5 x Upper Limit of Normal (ULN).&#xD;
&#xD;
          6. Adequate liver function (Serum total bilirubin ≤1.5 x ULN, and INR ≤ 1.5 x ULN, and&#xD;
             Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase&#xD;
             (ALP) ≤2.5 x ULN (≤ 5 x ULN for participants with liver metastases)). Participants&#xD;
             being treated with an anti-coagulant, such as warfarin or heparin, will be allowed to&#xD;
             participate provided that no prior evidence of an underlying abnormality in these&#xD;
             parameters exists.&#xD;
&#xD;
          7. Adequate cardiac function (Left Ventricular Ejection Fraction (LVEF) ≥ 50% or above&#xD;
             the lower limit of normal (LLN) for the Institution (whichever is lower). Cardiac&#xD;
             function should be assessed within 3 months prior to randomisation, but after&#xD;
             completion of any anthracycline-containing chemotherapy.&#xD;
&#xD;
          8. Willing and able to comply with all study requirements, including treatment, timing,&#xD;
             and/or nature of required assessments and follow-up.&#xD;
&#xD;
          9. Study treatment both planned and able to start within 7 days after randomisation&#xD;
             (note: subjects randomised on a Friday should commence treatment no earlier than the&#xD;
             following Monday).&#xD;
&#xD;
         10. Signed, written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Known allergy to the investigational product drug class or excipients in the&#xD;
             regorafenib.&#xD;
&#xD;
          2. Poorly-controlled hypertension (systolic blood pressure &gt;140mmHg or diastolic&#xD;
             pressure&gt; 90mmHg despite optimal medical management).&#xD;
&#xD;
          3. Participants with known, uncontrolled malabsorption syndromes.&#xD;
&#xD;
          4. Any prior anti-VEGF targeted therapy using small molecule VEGF TKIs (e.g. apatinib).&#xD;
             Prior anti-VEGF targeted monoclonal antibody therapies (e.g. bevacizumab and&#xD;
             ramucirumab) are permitted.&#xD;
&#xD;
          5. Treatment with any previous drug therapy within 2 weeks prior to first dose of study&#xD;
             treatment. This includes any investigational therapy.&#xD;
&#xD;
          6. Use of biological response modifiers, such as granulocyte colony stimulating factor&#xD;
             (G-CSF), within 3 weeks prior to randomisation.&#xD;
&#xD;
          7. Concurrent treatment with strong CYP3A4 inhibitors or inducers.&#xD;
&#xD;
          8. Palliative radiotherapy, unless more than 14 days have elapsed between completion of&#xD;
             radiation and the date of registration, and adverse events resulting from radiation&#xD;
             have resolved to&lt; Grade 2 according to CTCAE V4.03.&#xD;
&#xD;
          9. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to randomization.&#xD;
&#xD;
         10. Arterial thrombotic or ischaemic events, such as cerebrovascular accident, within 6&#xD;
             months prior to randomization.&#xD;
&#xD;
         11. Venous thrombotic events and pulmonary embolism within 3 months prior to&#xD;
             randomization.&#xD;
&#xD;
         12. Any haemorrhage or bleeding event ≥ Grade 3 according to CTCAE v4.03 within 4 weeks&#xD;
             prior to randomization.&#xD;
&#xD;
         13. Non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
         14. Interstitial lung disease with ongoing signs and symptoms.&#xD;
&#xD;
         15. Clinical hyperthyroidism or hypothyroidism. Note: non-clinically significant abnormal&#xD;
             TFTs (abnormal TSH and abnormal T3 and/or abnormal T4) considered to be due to sick&#xD;
             euthyroid syndrome is allowed.&#xD;
&#xD;
         16. Persistent proteinuria of ≥ Grade 3 according to CTCAE v4.03 (equivalent to &gt; 3.5g of&#xD;
             protein over 24 hours, measured on either a random specimen or 24 hour collection).&#xD;
&#xD;
         17. Uncontrolled metastatic disease to the central nervous system. To be eligible, CNS&#xD;
             metastases should have been treated with surgery and/or radiotherapy and the patient&#xD;
             should have been receiving a stable dose of steroids for at least 2 weeks prior to&#xD;
             randomization, with no deterioration in neurological symptoms during this time.&#xD;
&#xD;
         18. History of another malignancy within 2 years prior to randomization. Participants with&#xD;
             the following are eligible for this study:&#xD;
&#xD;
               1. curatively treated cervical carcinoma in situ,&#xD;
&#xD;
               2. non-melanomatous carcinoma of the skin,&#xD;
&#xD;
               3. superficial bladder tumours (T1a [Non-invasive tumour], and Tis[Carcinoma in&#xD;
                  situ]),&#xD;
&#xD;
               4. treated thyroid papillary cancer&#xD;
&#xD;
         19. Any significant active infection, including chronic active hepatitis B, hepatitis C,&#xD;
             or HIV. Testing for these is not mandatory unless clinically indicated. Participants&#xD;
             with known Hepatitis B/C infection will be allowed to participate providing evidence&#xD;
             of viral suppression has been documented and the patient remains on appropriate&#xD;
             anti-viral therapy.&#xD;
&#xD;
         20. Serious medical or psychiatric condition(s) that might limit the ability of the&#xD;
             patient to comply with the protocol.&#xD;
&#xD;
         21. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal&#xD;
             infertile, or use a reliable means of contraception. Women of childbearing potential&#xD;
             must have a negative pregnancy test done within 7 days prior to randomization. Men&#xD;
             must have been surgically sterilized or use a barrier method of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Pavlakis, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>AGITG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>INTEGRATE II Mailbox</last_name>
    <email>integrateii@ctc.usyd.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>accru@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Tanios Bekaii-Saab, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>accru@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center NCI Community Oncology Research Program</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Trial Coodinator</last_name>
      <email>accru@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Centres</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>45009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Bon Secours Cancer Institute</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>76065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>accru@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canberra Hospital</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>New South Wales</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coffs Harbour Health Campus</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Public Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle Private Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Port Macquarie Base Hospital</name>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Tweed Hospital</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ballarat Oncology and Haematology Services</name>
      <address>
        <city>Wendouree</city>
        <state>New South Wales</state>
        <zip>3355</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Darwin Hospital</name>
      <address>
        <city>Tiwi</city>
        <state>Northern Territory</state>
        <zip>0810</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Townsville Hospital</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>INTEGRATE II Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Womens Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Sunshine Coast</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Ashford</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>700</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St John of God Hospital Subiaco</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PEI Cancer Treatment Centre, Queen Elizabeth Hospital</name>
      <address>
        <city>Charlottetown</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Nova Scotia</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Health Network Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Hospital East</name>
      <address>
        <city>Chiba</city>
        <state>Kashiwa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Kita</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea - Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea - Yeouido St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System - Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System - Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>+61 2 9562 5000</phone>
      <email>INTEGRATEII@ctc.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital (NTUH)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital (TPVGH)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <email>SM_AGITG_1006465@INCResearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Locally recurrent</keyword>
  <keyword>Oesophago-gastric junction</keyword>
  <keyword>Stomach</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Undifferentiated Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

